Novo Nordisk Reports Mixed 2025 Results, Projects 2026 Adjusted Sales Decline Amid Headwinds
Summary
Novo Nordisk reported 2025 financial results and issued a 2026 outlook projecting a decline in adjusted sales and operating profit due to pricing pressures and competition, despite a significant one-time revenue reversal and positive pipeline developments.
Key Events
-
2025 Financial Performance
Reported 2025 sales of DKK 309.1 billion (+10% at constant exchange rates) and operating profit of DKK 127.7 billion (+6% at constant exchange rates), driven by strong Obesity care sales (+31% CER) and Wegovy® sales (+41% CER).
-
2026 Adjusted Outlook Decline
Projected 2026 'adjusted' sales and operating profit growth to decline by 5-13% at constant exchange rates, reflecting significant pricing headwinds, patent expiry, and competition. This follows a previous 6-K on 2026-02-03 that also indicated a decline in the outlook.
-
Significant 340B Revenue Reversal
Will recognize a one-time revenue reversal of USD 4.2 billion (approx. DKK 28 billion) in Q1 2026 due to a favorable legal ruling regarding the 340B Drug Pricing Program, which will positively impact non-adjusted 2026 figures.
-
Mixed R&D Updates
Oral Wegovy® pill (semaglutide 25 mg) approved by US FDA and launched for obesity. CagriSema Phase 3 trials for type 2 diabetes successfully completed with superior results, and submitted for US FDA approval in weight management. However, Phase 3 trials for oral semaglutide in Alzheimer's disease failed to show efficacy, and several other pipeline projects were terminated.
Analysis
Novo Nordisk's comprehensive annual report for 2025 reveals a complex financial picture and a challenging outlook for 2026. While 2025 saw solid sales growth, the company projects a significant decline in 'adjusted' sales and operating profit for 2026 (down 5-13% at constant exchange rates). This adjusted guidance excludes a substantial one-time revenue reversal of USD 4.2 billion related to the 340B Drug Pricing Program, which will positively impact non-adjusted 2026 figures. The underlying decline is attributed to lower realized prices from the 'Most Favoured Nations' agreement in the US, semaglutide patent expiry in some international markets, and intensifying competition. Additionally, the company announced the failure of its Phase 3 trials for oral semaglutide in Alzheimer's disease, a notable R&D setback, and terminated several other pipeline projects. Two Executive Vice Presidents are departing, with new appointments announced. To offset some of these concerns, Novo Nordisk initiated a new DKK 15 billion share repurchase program, signaling a commitment to shareholder returns.
At the time of this filing, NVO was trading at $50.72 on NYSE in the Life Sciences sector, with a market capitalization of approximately $260.8B. The 52-week trading range was $43.08 to $93.80. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.